Overview:

Summary

The industry analysis specialist’s new report, “Herpes Simplex - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global herpes simplex market. The report identifies the key trends shaping and driving the global herpes simplex market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global herpes simplex sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key driver and challenges of the global herpes simplex market. Its scope includes:
- Annualized global herpes simplex market revenues data from 2001 to 2009, forecast forward for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action include DNA polymerase inhibitors, Helicase-primase inhibitors, NFkB regulators, HSV-2 gene and nectin-1 receptor targetters, viral maturation inhibitors and PDI inhibitors.
- Analysis of the current and future market competition in the global herpes simplex market. Key market players covered are BioAlliance Pharma, Nutra Pharma Corporation and AiCuris GmbH & Co. KG.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with herpes simplex therapeutics.

Reasons to buy

The report will enhance your decision making capability in a rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global herpes simplex market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global herpes simplex market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain the competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global herpes simplex market landscape? – Identify, understand and capitalize.

Companies Mentioned

BioAlliance Pharma
Nutra Pharma Corporation
AiCuris GmbH and Co. KG

1 Table of contents 3
1.1 List of Tables 4
1.2 List of Figures 4
2 Herpes Simplex Therapeutics Market: Market Characterization 5
2.1 Overview 5
2.2 Herpes Simplex Therapeutics Market Size 5
2.3 Herpes Simplex Therapeutics Market Forecast and CAGR 7
2.4 Drivers and Barriers for the Herpes Simplex Therapeutics Market 8
2.4.1 Drivers for the Herpes Simplex Therapeutics Market 8
2.4.2 Barriers for the Herpes Simplex Therapeutics Market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 Herpes Simplex Therapeutics Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Portfolio for Major Marketed Products in the Herpes Simplex Therapeutics Market 11
3.3.1 Zovirax (Acyclovir) 11
3.3.2 Famvir (Famciclovir) 12
3.3.3 Valtrex (Valacyclovir) 13
3.4 Key Takeaway 16
4 Herpes Simplex Therapeutics Market: Pipeline Assessment 17
4.1 Overview 17
4.1.1 Technology Trends Analytical Framework 17
4.2 Herpes Simplex Therapeutics – Promising Drugs under Clinical Development 18
4.3 Molecule Profiles for Promising Drugs under Clinical Development 19
4.3.1 BA-021 (Acyclovir Lauriad) 19
4.3.2 RPI-78M 19
4.3.3 AIC316 20
4.4 Herpes Simplex Therapeutics Market – Pipeline Assessment by Mechanism of Action 20
4.5 Herpes Simplex Therapeutics Market – Pipeline Assessment by Clinical Phase of Development 21
4.5.1 Herpes Simplex Therapeutics – Phase III Clinical Pipeline 21
4.5.2 Herpes Simplex Therapeutics – Phase II Clinical Pipeline 22
4.5.3 Herpes Simplex Therapeutics – Phase I Clinical Pipeline 22
4.5.4 Herpes Simplex Therapeutics – Preclinical Pipeline 23
4.5.5 Herpes Simplex Therapeutics – Discovery Pipeline 23
4.6 Discontinued/Suspended Drugs for Herpes Simplex 23
4.7 Key Takeaway 24
5 Herpes Simplex Therapeutics Market: Implications for Future Market Competition 25
6 Herpes Simplex Therapeutics Market: Future Players in the Herpes Simplex Therapeutics Market 27
6.1 BioAlliance Pharma 27
6.1.1 Overview 27
6.1.2 Business Description 27
6.1.3 Antiviral Pipeline Portfolio 28
6.1.4 Herpes Simplex Pipeline Portfolio 28
6.2 Nutra Pharma Corporation 29
6.2.1 Overview 29
6.2.2 Business Description 29
6.2.3 Anti-Viral Pipeline Portfolio 30
6.2.4 Herpes Simplex Pipeline Portfolio 30
6.3 AiCuris GmbH and Co. KG 30
6.3.1 Overview 30
6.3.2 Herpes Simplex Pipeline Portfolio 31
7 Herpes Simplex Therapeutics Market: Appendix 32
7.1 Definitions 32
7.2 Scope of Pipeline Research 32
7.3 Acronyms 32
7.4 Research Methodology 33
7.4.1 Coverage 33
7.4.2 Secondary Research 34
7.4.3 Forecasting 34
7.4.4 Primary Research 37
7.4.5 Expert Panel Validation 37
7.5 Contact Us 37
7.6 Disclaimer 37
7.7 Sources 38

1.1 List of Tables
Table 1: Herpes Simplex Therapeutics Market, Global, Revenues ($m), 2001-2009 6
Table 2: Herpes Simplex Therapeutics Market, Global, Market Forecasts ($m), 2009-2017 7
Table 3: Major Marketed Products Comparison in Herpes Simplex Market, 2010 16
Table 4: Simplex Therapeutics Market – Most Promising Drugs under Clinical Development, 2010 18
Table 5: Herpes Simplex Market – Phase III Clinical Pipeline, 2010 21
Table 6: Herpes Simplex Therapeutics Market – Phase II Clinical Pipeline, 2010 22
Table 7: Herpes Simplex Market – Phase I Clinical Pipeline, 2010 22
Table 8: Herpes Simplex Market – Preclinical Pipeline, 2010 23
Table 9: Herpes Simplex Market – Discovery Pipeline, 2010 23
Table 10: Herpes Simplex Market – Discontinued Drugs, 2010 23
Table 11: BioAlliance Pharma – Anti-Viral Pipeline Portfolio, 2010 28
Table 12: BioAlliance Pharma – Herpes Pipeline Portfolio, February 2010 28
Table 13: Nutra Pharma Corporation – Anti-viral Pipeline Portfolio, 2010 30
Table 14: Nutra Pharma Corporation – Herpes Pipeline Portfolio, 2010 30
Table 15: AiCuris GmbH & Co. KG – Herpes Simplex Pipeline Portfolio, 2010 31

1.2 List of Figures
Figure 1: Herpes Simplex Therapeutics Market, Global, Revenues ($m), 2001-2009 6
Figure 2: Herpes Simplex Therapeutics Market, Global, Market Forecast ($m), 2009-2017 7
Figure 3: Opportunity and Unmet Need in the Herpes Simplex Market, 2010 9
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Herpes Simplex Market, 2010 11
Figure 5: Technology Trends Analytic Framework, Herpes Simplex Pipeline, 2010 17
Figure 6: Technology Trends Analytic Framework of the Herpes Simplex Pipeline – Description, 2010 18
Figure 7: Herpes Simplex Clinical Pipeline – by Mechanism of Action, 2010 20
Figure 8: Herpes Simplex Clinical Pipeline – by Phases of Development, 2010 21
Figure 9: Implications for Future Market Competition in Herpes Simplex Market, 2010 25
Figure 10: Herpes Simplex, Global, Companies That Have the Highest Number of Molecules in the Pipeline, 2010 27
Figure 11: GlobalData Methodology, 2010 33
Figure 12: GlobalData Market Forecasting Model, 2010 36